A recent trial to study safety and effectiveness of a personalized cancer vaccine combined with immunotherapy drug Pembrolizumab will expand after promising preliminary data was presented. Researchers reported data on the first 10 patients with head and neck cancer.
Personalized cancer vaccine clinical trial to expand following promising early results
A recent trial to study safety and effectiveness of a personalized cancer vaccine combined with immunotherapy drug Pembrolizumab will expand after promising preliminary data was presented. Researchers reported data on the first 10 patients with head and neck cancer.